In total, these findings suggest that LRRK2 kinase activity plays a crucial role in the development of DSS-induced colitis, which indicates that targeting LRRK2 kinase activity provides a potential method for inhibiting the development of colitis and colitis-associated cancer. This evidence concerns the gene LRRK2 and colitis.